introDuCtion
An elevated pulse pressure (PP) consistently predicts increased cardiovascular risk in a variety of populations. In normal and hypertensive populations, an increased PP is a risk factor for coronary heart disease, chronic heart failure (CHF) and cardiovascular mortality. [1] [2] [3] [4] [5] [6] [7] In patients who have undergone percutaneous or surgical revascularisation, a high PP predicts total mortality. 8 Similarly, in patients with left ventricular systolic dysfunction (LVSD) after myocardial infarction, an increased PP predicts total and cardiovascular mortality and re-infarction. 9 A high PP in these patients is caused by a decreased aortic elasticity probably due to advanced atherosclerosis, and is therefore related to an adverse outcome.
The prognostic value of PP in patients with CHF is less clear. In the first study to look at the relationship between PP and outcome, the SOLVD investigators found that a high PP predicted adverse outcome. 10 However, a significant proportion of patients in the SOLVD trials did not have CHF, but asymptomatic left ventricular systolic dysfunction. Approximately one-third of patients had New York Heart Association (NYHA) class II or III CHF. In contrast, in patients hospitalized with acute decompensated heart failure, low PP appeared to be an independent predictor of mortality. 11 In these patients, a low PP probably reflects a decreased cardiac function and is therefore related to an increased mortality. The aim of the current study is to examine the predictive value of PP on mortality in patients with stable but advanced CHF (NYHA class III or IV).
methoDS

Patients
All patients of the present study had been part of the Prospective Randomised study of Ibopamine on Mortality and Efficacy (PRIME) -II study. 12 Blood pressure was measured at the randomisation visit, as per the usual practice of the participating centres. Details of inclusion and exclusion criteria have been previously published. 12 In brief, 1906 patients with advanced chronic heart failure (NYHA Class III-IV) were randomised to ibopamine, an oral dopamine agonist, or placebo. The primary endpoint of the study was all cause mortality. Patients were aged 18-80 years, and already received optical medical treatment with angiotensin-converting enzyme (ACE) inhibitors (if tolerated), diuretics, and when indicated digoxin and vasodilators. Evidence of left ventricular dysfunction had to be demonstrated by one or more of the following techniques; (i) left ventricular ejection fraction (LVEF) < 35% (measured by radio nuclide or contrast ventriculography, or by echocardiography), (ii) left ventricular internal end-diastolic diameter > 60 mm, or a fractional shortening < 20% on echocardiography, or (iii) cardiothoracic (CT) ratio on chest X-ray > 0.50. All patients gave written informed consent before inclusion in the study.
measurement of plasma neurohormones
In the PRIME II Study, 427 patients were enrolled in the Netherlands. From these 427 patients, 372 patients agreed to participate in a predefined neurohormonal substudy. Blood was collected from an intravenous cannula after patients had rested in the supine position for more than 30 minutes. Samples were poured into chilled 10 ml tubes containing EDTA (19 mg) and aprotinin (1000 kIU Figure 1 were calculated using univariable Logrank survival analysis (PROC LIFETEST, SAS Institute Inc.). In addition, a multivariable Cox proportional hazards model (PROC PHREG, SAS Institute Inc.) was used, including well known prognostic markers of mortality in CHF patients. 14 Beside PP, the following variables were included: mean arterial blood pressure (1/3 x systolic blood pressure +2/3 x diastolic blood pressure), age, left ventricular ejection fraction, functional New York Heart Association (NYHA) class, heart rate, body weight, diabetes, estimated glomerular filtration rate (Cockcroft-GaultGFRc = [(140-age in years) × (body weight in Kg)] / (72 × serum creatinine in mg/dl)), use of ibopamine, ACE-inhibitors, or betablockers.
The assumption of linearity was tested by fractional polynomials (SASA software version 11.5, and STATA version 8.2, Stata Corp. 2004). Linearity was found in all variables.
Possible interactions were tested between pulse pressure and systolic blood pressure, diastolic blood pressure, age, and heart rate. No correction has been made for multiple hypothesis testing since this, because of the small sample and endpoint size, was an exploratory study searching for parameters requiring confirmation in subsequent adequately powered studies. To distinguish between patients with and without a probably increased aortic stiffness, a subgroup analysis was performed in patients with a pulse pressure above and below the median pulse pressure of 45 mmHg.
A separate analysis was done to establish factors predicting the levels of ANP and BNP. All variables presented in table 1 were univariably tested in a linear regression model (PROC REG, SAS Institute Inc.). Variables with a p-value <0.1 in the univariable analysis were included into a mutivariable linear regression model (PROC REG, SAS Institute Inc.). All tests were two-sided. Data are presented as means ± standard errors of the mean. A p-value of < 0.05 was considered as statistically significant.
reSultS
A total of 1906 patients were included in the original study. Measurements of systolic and/or diastolic blood pressure were missing in 5 patients. The present analysis was performed on the remaining 1901 patients. Mean follow up was 11.2 (range 0 -36) months. Kaplan-Meier survival analysis demonstrated that overall one year mortality was 22.5%. Baseline characteristics of the patient population are presented in table 1. There were substantial differences between patients with lower and higher pulse pressures (table  1) . Patients with a PP below the median value of 45 mmHg had a significantly lower systolic and diastolic blood pressure, were younger, more often male, had a lower left ventricular ejection fraction, a higher heart rate, were less symptomatic, less diabetes, and had better renal function.
Mean pulse pressure was 47 (range 11 -135) mmHg. Pulse pressure quartiles were: ≥55 mmHg (Q1; n = 506), 45 -55 mmHg (Q2; n = 496), 35 -45 mmHg (Q3; n = 430) and ≤ 35 mmHg (Q4; n = 469). Survival in each quartile of pulse pressure is presented in Figure  1 . Survival in the first three quartiles were similar (Q1: 62.9 %; Q2: 65.1 %; Q3: 65.5 %). Patients with a pulse pressure ≤35 mmHg had a significantly lower survival (Q4: 48.1 %; Logrank: p = 0.0005). 
multivariable analysis
Multivariable (independent) predictors of mortality are presented in Table 2 . Both lower PP [hazard ratio (HR) 0.91 per 10 mmHg; 0.93-0.99] and lower MAP (HR 0.87 per 10 mmHg; 0.79-0.96) were independently related to increased mortality. Other significant prognostic markers were LVEF, heart rate, NYHA Class, glomerular filtration rate, diabetes, the use of ibopamine, and the non-use of ACE-inhibitors or betablockers (Table 2) . Table 3 demonstrates that in patients with a PP below the median value of 45 mmHg, PP was stronger associated with mortality than MAP. In contrast, in patients with a PP equal to or above the median value of 45 mmHg, MAP was stronger associated with mortality than PP (Table 4) . 
natriuretic peptides
From the 427 patients that were included in the Netherlands, 372 patients agreed to participate in a predefined neurohormonal substudy. Both N-ANP, BNP, and NT-BNP were significantly increased in patients with a pulse pressure < 45 mmHg (Figure 2 ). This relation remained statistically significant after adjustment for systolic and diastolic blood pressure, glomerular filtration rate, and other possible confounders as described in 
DiSCuSSion
This is the first study of the prognostic value of PP in patients with advanced CHF. A low PP is independently associated with increased mortality in this population. In patients with a PP below the median value of 45 mmHg, the magnitude of the excessive risk conferred by a low PP even exceeds that of mean arterial blood pressure, which is a well recognised indicator of poor prognosis. [15] [16] [17] Notably, in patients with a pulse pressure < 45 mmHg, mean arterial blood pressure was a better predictor of mortality than pulse pressure. In addition, elevated natriuretic peptides were significantly and independently related to lower PP.
The only previous study of the predictive value of PP that included patients with CHF was a retrospective analysis of the SOLVD trial. 10 In contrast to the current study a high PP predicted a worse clinical outcome. The most important difference between the SOLVD study and the current analysis is the NYHA class of the patients studied. The SOLVD analysis included patients from both the prevention and treatment trials. Those in the prevention trial had asymptomatic left ventricular systolic dysfunction (n=4228) whereas those in the treatment trial (n=2569) had predominantly NYHA class II, with a minority of NYHA class III, CHF. This was a study, therefore, of asymptomatic left ventricular systolic dysfunction (LVSD) and mild CHF which is a markedly different population to those with advanced CHF in PRIME II. The SOLVD analysis did not present a detailed breakdown of the subgroup analysis between asymptomatic LVSD and symptomatic LVSD populations but did state that there were "similar results" in both groups. 10 In contrast to patients with mild chronic heart failure, it was recently demonstrated that a lower PP was related to increased mortality in acutely decompensated heart failure. 11 Patients in the lowest tertile (PP < 43 mmHg) had a 2.5 times increased mortality risk compared to patients in the highest tertile (PP > 59 mmHg).
There are several explanations for the apparent discrepancy of the predictive value of PP in different populations. PP is mainly determined by stroke volume and arterial compliance. When systolic left ventricular function and stroke volume are normal, an elevated pulse pressure is thought to principally reflect decreased aortic elasticity. The resulting increase in pulsatile load is thought to have an adverse effect on cardiac function and result in an increased risk of clinical events. In addition, arterial compliance is related to atherosclerosis, and a higher PP in patients with a normal cardiac function probably reflects more severe atherosclerosis. This scenario is thought to apply especially to hypertension and stable coronary heart disease. [1] [2] [3] [4] [5] [6] [7] In patients with post myocardial infarction left ventricular systolic dysfunction, asymptomatic left ventricular systolic dysfunction and mild CHF, PP is driven both by left ventricular dysfunction (decreased stroke volume and lower PP) and by a decreased aortic elasticity (higher PP). As a higher PP was related to cardiovascular events in these patients as well, the effects of a decreased aortic elasticity seem to be more important than the effects of a decreased stroke volume. [8] [9] [10] In the present study, we analysed the effects of PP on mortality in advanced CHF patients. Obviously, the effects of a decreased stroke volume, reflected by a lower PP, become more important than a decreased aortic elasticity. This is further supported by the finding that the effects of PP were more pronounced in patients with a lower PP, probably reflecting a group of patients without a decreased aortic elasticity.
In 1989, Stevenson and Perloff 18 demonstrated that proportional PP (systolic -diastolic blood pressure / systolic blood pressure) correlated well with cardiac index (r 2 = 0.82). In patients with a proportional PP of less than 25 %, sensitivity and specificity for a cardiac index less than 2.2 L/min/m 2 were 91 % and 83 % respectively. These findings were supported by the results of Shah et al. 19 PP was the only multivariable predictor of pulmonary capillary wedge pressure (PCWP) > 18 mmHg ("wet patients"), and a cardiac index of ≤ 2.2 L/min/m 2 ("cold patients"). In a more recent study by Nohria et al. 20 event-free survival was significantly lower in the "wet and cold" patients, compared to the "dry and warm" patients. These data are in line with the present study, where increased natriuretic peptides fit well with the "wet and cold" profile.
limitations of the study
It is important to note that this analysis is exploratory in nature and was not pre-specified in the PRIME II protocol. In particular, the separation between patients with higher and lower pulse pressure was a post-hoc analysis. The data collected is in a clinical trial setting and we recognise that the findings require verification in prospective epidemiological studies of appropriate populations. Blood pressure measurement was not performed in a uniform manner. This may be regarded as a criticism but reflects real-life practice. The PRIME II trial was carried out in the late 1990s before betablockers were standard CHF management and thus the effect of betablockers on the predictive value of PP on mortality in advanced CHF is unknown.
ConCluSionS
Pulse pressure provides a readily available, clinic or bedside prognostic indicator in advanced CHF. Low pulse pressure independently predicts increased mortality. Moreover, low pulse pressure is independently related to increased natriuretic peptides.
